COGNIZANT 20-20 INSIGHTS

Taking Control of the

MLR Review Process

In todays increasingly automated, hyper-

connected world, pharmaceuticals
companies must ensure that medical, legal
and regulatory reviews are accurate, efficient,
and risk-averse.

Cognizant 20-20 Insights | March 2017

Cognizant 20-20 Insights

EXECUTIVE SUMMARY

Pharmaceuticals and biotech companies routinely undergo medical, legal, and regulatory
(MLR) review to ensure that their products claims, promotions, and training programs are
medically accurate and in compliance with Federal Drug Administration (FDA) standards
and other regulations.

This typically requires enterprises to establish promotional review committees (PRC)

made up of cross-functional teams comprising medical, legal and regulatory experts.
Understandably, PRCs must be extremely knowledgeable and precise; otherwise, drug
companies run the risk of receiving warning letters from the FDA. The MLR process requires
project managers to work closely with reviewers and key stakeholders from marketing
and advertising agencies to corporate leadership to ensure that everyones voice is
heard. Simultaneously, marketing managers must get their products to market in a timely
manner and avoid delays that can negatively affect financial performance.

Promotional materials target either consumers or healthcare professionals, and are

distributed across various types of media, including print (brochures, posters, banner ads,
flashcards, etc.) and digital (websites, mobile apps, TV commercials, interactive e-mails/
PDFs, etc.).

This white paper explores the different phases of the MLR process and how analytics can be
applied to answer key questions project/brand managers face, such as:

How much time does it take for promotional material to reach consumers?

What percentage of these materials is used versus the volume produced?

What are the process bottlenecks that hold up the distribution of these materials?

What KPIs should be monitored to help project managers track the material throughout
the process (e.g., at what stage is it stuck in the pipeline? What are the reasons behind
the delay?).

Taking Control of the MLR Review Process | 2

Cognizant 20-20 Insights

PROMOTIONAL MATERIAL Key marketing team members and external

REVIEW agencies work together to develop project
requirements and timelines based on the tactical
The review process for promotional material calendar and business goals. Agencies then
typically starts with strategic planning create an initial concept, and submit it to the
progressing through multiple stages over time. marketers for their review. Following that step,
Figure 1 depicts the three broad phases the project moves to the next stage for kick-off
(upstream, midstream, and downstream) with key stakeholders.
of promotional material development and
dissemination. Midstream Phase

Upstream Phase This phase begins with a kick-off meeting to help

project managers connect with various stake-
This phase starts with strategic discussions holders; introduce the promotion/marketing
between marketing and leadership teams to initiative; and assess how team members can
review the market, the brand, and the proposed leverage their area of expertise. The team
product portfolio, then moves to brand typically includes key personnel from marketing;
positioning and tactical planning. Once this stage project managers; reviewers (medical, legal, and
is completed, organizations usually engage regulatory); external vendors (print and tech-
external agencies to gather ideas and nology); senior leadership, and consultants.
recommendations for the product portfolio.

Dissecting the Review Process

UPSTREAM PHASE

Engage Initial
Strategic Agency / Concept Marketing Submit for
Planning Initial Submitted to Reivew Kick-off
Discussion Marketing

MIDSTREAM PHASE Resubmitted

Not Ad Agency Marketing

Medical, Review &
Initial Legal & Approved Edits
Submit
Kick-off Regulatory
(MLR) Approved
Submit for
Review Production

DOWNSTREAM PHASE

Blueprint Final
Production: Project Production Print / Submit Release
Print or Manager Review of Digital to FDA to Market
Digital Reivew Real Production
Product

Reject

Figure 1

Taking Control of the MLR Review Process | 3

Cognizant 20-20 Insights

For pharmaceuticals companies,

accelerating time to market
requires a review process that
is informed, cost-efficient and
risk-averse.
The purpose is to shares ideas, offer suggestions, PROBLEM STATEMENT
and identify potential challenges/gaps that
could stall or slow the initiative. For pharmaceuticals companies, accelerating
time to market requires a review process that is
Following the kick-off meeting, marketing and informed, cost-efficient and risk-averse.
external agency partners typically go through
multiple iterations of the project concept Typical Challenges
before presenting it to reviewers for their Typically, marketing initiatives are based on an
respective approvals. Medical, legal, and organizations requirements or developed in
regulatory reviewers scrutinize the content of response to industry dynamics. Nonetheless,
the material to ensure that it is correct, reviewers are often time-challenged due to
consistent, and in line with the rules, regulations, industry resource reductions and competing
and FDA guidelines within their area of expertise. initiatives that also demand their attention.

Downstream Phase In the following pages, we will examine how to

At this stage, the vendor submits the blueprint develop and optimize an MLR process that will
for print and/or digital for final review and signoff have the desired impact and make the most of an
by the client organization to ensure that all organizations current resources. Most often, the
requested changes have been incorporated. This number of projects evaluated or conceptualized
usually entails multiple exchanges between the at the strategic level declines before the next
vendor and the client prior to signoff. Digital stage of project creation and review. Other
projects typically go through more iterations projects are shelved before they reach the next
before they are submitted to the FDA prior to stage of production due to factors such as budget
hitting the market. cuts and market shifts. End users (e.g., sales
representatives, healthcare professionals,
pharmacies, and patients) end up ordering only a
fraction of products produced and stored in
warehouses. This funnel structure (see Figure 4,
page 7) requires several tactical adjustments in
order to deliver the expected outcome.

Taking Control of the MLR Review Process | 4

Cognizant 20-20 Insights

To determine the scope and goals of a project, companies must

define key performance indicators (KPIs), which will help gauge the

effectiveness of their efforts as they work through the process of

preparing materials for MLR review.

APPLYING AN ANALYTICAL communicate to project teams within and

APPROACH outside the organization (see Figure 2).

To address this situation, we recommend a While there are thousands of KPIs to choose
systematic process for evaluating a project and from, many companies find it difficult to select
plugging in the right parameters at the right time those that fit the needs of their business and
to achieve a common goal. All key stakeholders marketing requirements. Research tells us that
(marketing teams, reviewers, external agencies, less than 10% of all the metrics that are collected,
leadership) must be aligned and in place from a analyzed, and reported in businesses are used to
projects beginning. A thorough analysis of key inform decision making. Even worse, 90% of the
areas for improvement must be performed, and metrics produced end up overwhelming decision
potential bottlenecks identified. To determine makers, who are thirsting for insights.1
the scope and goals of a project, companies must
define key performance indicators (KPIs), which Analytics technologies enable companies to
will help gauge the effectiveness of their efforts examine and decipher vast amounts of data that
as they work through the process of preparing can be used to deepen knowledge, enlighten
materials for MLR review. decisions, and develop KPIs that suit their precise
requirements. KPIs are defined around the needs
KPIs must be clearly defined and quantifiable, in of MLR teams and regularly monitored to help
line with stated business goals, and easy to spot gaps and target opportunities for improving
accuracy and efficiency.

Developing Relevant KPIs

Define

Measure Analyze
Key
Performance
Indicators

Implement Solve

Figure 2

Taking Control of the MLR Review Process | 5

Cognizant 20-20 Insights

CREATING MEANINGFUL KPIs At the same time, KPIs must be monitored over a
sufficient period, roughly three to six months, to
There are numerous KPIs for tracking process properly assess their value. Having a
efficiency. Figure 3 lists some of the most comprehensive view of product KPIs helps
common ones. marketers and reviewers streamline project
planning, improve inputs, simplify the review
These KPIs can help make the entire MLR process
process, and produce marketing material that is
more efficient, and potentially generate more
accurate, relevant and effective.
returns for the business (See Figure 4, page 7).

Prioritizing KPIs

Key Performance
S No. Description Value-Add
Indicators (KPIs)

1 Entire Project Days to close a project, from initial kick-off to Serves as top-level health metric to account
Duration FDA submission. for project duration.

2 Duration by Project Classification of duration by project type Predicts project completion based on type.
Type (e.g., websites, e-mail, marketing collateral).

3 Duration of Each Classification of project duration at each Uncovers bottlenecks throughout the
Stage of the step in the review process (e.g., medical, process (high project volumes, changing
Process regulatory, legal review). priorities, product acquisitions, etc.).

4 Cycles/Churn at Number of rejections by medical/legal/ Helps assess the bottlenecks that might
Each Stage regulatory/IT throughout the review process. delay project completion.

5 Reasons for Number of projects rejected and the reasons Helps understand the cause of bottlenecks
Additional Cycles cited by the reviewer. (unclear guidance from marketing, incorrect
files, agency errors).

6 Stakeholder Assessment of the key stakeholders who are Extends accountability to include not only
(Internal/External) accountable for rejections at any stage. the marketing team, but also internal/
Accountability external parties.

7 Products Produced Number and names of products produced Enables the company to keep a close watch
& Available in and their availability in the inventory of on products in inventory and their
Inventory internal/external vendors. warehousing cost.

8 Products Ordered Number of products ordered by end users Helps assess actual product utilization.
(sales rep, HCP, patient, etc.).

Figure 3

Taking Control of the MLR Review Process | 6

Cognizant 20-20 Insights

Aligning KPIs & Measurements: The Current Process

Marketing Materials MLR Review Produced Ordered

(n=1000) (n=800) (n=500) (n=150)

Impact

KPIs measured at each stage

KPI 16 KPI 7 KPI 8
Figure 4

Aligning KPIs & Measurements: The Proposed Solution

Marketing Materials MLR Review Produced Ordered

(n=700) (n=500) (n=300) (n=100)
More Focused Materials

Increased
Impact

Increased Productivity RAMP

(Reviewers, Agencies, Marketers & Production)
Figure 5

LOOKING FORWARD workload for reviewers, agencies, sales channels,

and production resources (see Figure 5). This
The MLR process depends on balancing the approach (as detailed in the Quick Take on page
collective efforts of reviewers, marketing teams, 8) allows pharmaceuticals and biotech companies
agencies, and production (print/digital). The goal to leverage their investment in strategic
is to produce promotional materials that are promotions, assure the quality and integrity of
accurate, timely, focused, and adaptable for use their product portfolio, bring new products to
in future promotions. In this way, companies can market faster, and improve the MLR review
avoid flooding the market and overwhelming end process at every stage.
users with too much information, and reduce the

Taking Control of the MLR Review Process | 7

Cognizant 20-20 Insights

QUICK TAKE

Leading Pharma Company Takes Hold

of the MLR Process
The client, a top pharmaceuticals company, utilized a robust promotional/educational
material review process. All materials (brochures, ads, flashcards, rep-education assets,
etc.) from the marketing team required multiple approvals by various groups (medical,
regulatory, legal, compliance, IT) before going live. The client wanted to identify key
bottlenecks and reduce turnaround time initially by one-third and eventually by one-half.

We collaborated with the company to:

Conduct a comprehensive data analysis, tracking the average duration of the

materials at each stage of the review process using historical data.

Identify relevant KPIs that could ferret out bottlenecks in the review process.

This analysis considered various factors brand, media type (print vs. digital),
material type (ad board, brochure, flashcards, etc.) to understand the KPIs from
different perspectives.

Create an executive-level, interactive dashboard that marketing directors could

use to assess the process month to month.

Because of this analysis, the client can now take advantage of:

Interactive insights that enable the companys marketing team to gauge performance
against KPIs and identify obstacles monthly.

Information that enables the companys senior leadership to take immediate action
and move projects faster through the review process.

Reduced turnaround time (TAT) by ~40%.

Taking Control of the MLR Review Process | 8

Cognizant 20-20 Insights

FOOTNOTE

1
www.ap-institute.com/what-is-a-key-performance-indicator.aspx.

REFERENCES

http://blog.themsls.org/2014/07/7-essential-considerations-about-promotional-material-review-and-approval/.

www.pharmexec.com/promotional-review-committees-how-achieve-high-performing-teams-0.

ABOUT THE AUTHORS

Ketki Gupta Ketki Gupta has more than nine years of experience in the field of
analytics for the pharmaceuticals industry. Ketki has worked on
Manager, Cognizant a wide range of analytics projects, including promotion response
Analytics & Information modeling, sales force effectiveness, ROI for campaign management,
Management Practice and speaker program compliance and effectiveness. She also
[email protected] focuses on consulting and analytics around process efficiencies
in various departments across the pharma industry. She holds a
masters degree in Applied Operational Research and a bachelors
degree in statistics from Delhi University.

Saurabh Arora Saurabh Arora has more than nine years of experience in consulting
and analytics, solving quantitatively challenging business problems
Senior Associate, using advanced analytical tools. Saurabh has worked on a variety
Cognizant Analytics & of projects involving operation efficiency analytics (including
Information Management MLR review process optimization), market research, marketing
Practice management, regression model monitoring, and sales force sizing
[email protected] and structure for clients throughout the U.S. and Europe. He holds
an M.B.A. degree from the Indian Institute of Foreign Trade, New
Delhi, and a bachelors degree in statistics from Delhi University.

Taking Control of the MLR Review Process | 9

ABOUT COGNIZANT ANALYTICS
Within Cognizant, as part of the social-mobile-analytics-cloud (SMAC) stack of businesses under our emerging business accelerator (EBA),
the Cognizant Analytics unit is a distinguished, broad-based market leader in analytics. It differentiates itself by focusing on topical,
actionable, analytics-based solutions coupled with our consulting approach, IP-based nonlinear platforms, solution accelerators and a
deeply entrenched customer-centric engagement model. The unit is dedicated to bringing insights and foresights to a multitude of industry
verticals/domains/functions across the entire business spectrum. We are a consulting-led analytics organization that combines deep domain
knowledge, rich analytical expertise and cutting-edge technology to bring innovation to our multifunctional and multinational clients;
deliver virtualized, advanced integrated analytics across the value chain; and create value through innovative and agile business delivery
models. www.cognizant.com/enterpriseanalytics.

ABOUT COGNIZANT
Cognizant (NASDAQ-100: CTSH) is one of the worlds leading professional services companies, transforming clients business, operating and
technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative
and efficient businesses. Headquartered in the U.S., Cognizant is ranked 230 on the Fortune 500 and is consistently listed among the most
admired companies in the world. Learn how Cognizant helps clients lead with digital atwww.cognizant.comor follow us @Cognizant.

World Headquarters European Headquarters India Operations Headquarters

500 Frank W. Burr Blvd. 1 Kingdom Street #5/535 Old Mahabalipuram Road
Teaneck, NJ 07666 USA Paddington Central Okkiyam Pettai, Thoraipakkam
Phone: +1 201 801 0233 London W2 6BD England Chennai, 600 096 India
Fax: +1 201 801 0243 Phone: +44 (0) 20 7297 7600 Phone: +91 (0) 44 4209 6000
Toll Free: +1 888 937 3277 Fax: +44 (0) 20 7121 0102 Fax: +91 (0) 44 4209 6060

Copyright 2017, Cognizant. All rights reserved. No part of this document may be reproduced, stored in a retrieval system, transmitted in any form or by any means,electronic, mechanical,
photocopying, recording, or otherwise, without the express written permission from Cognizant. The information contained herein is subject to change without notice. All other trademarks
mentioned herein are the property of their respective owners.

TL Codex 2522